| scholarly article | Q13442814 |
| P2093 | author name string | Jorgensen RA | |
| Hofmann AF | |||
| Lindor KD | |||
| Dickson ER | |||
| Rossi SS | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Physicochemical and physiological properties of cholylsarcosine. A potential replacement detergent for bile acid deficiency states in the small intestine | Q28316095 | ||
| Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis | Q28335479 | ||
| Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis | Q39514969 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis | Q43214926 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Effect of cholylsarcosine on hepatic cholesterol and bile acid synthesis and bile secretion in rats | Q44896828 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. | Q50878460 | ||
| Evaluation of colchicine therapy in primary biliary cirrhosis | Q68139571 | ||
| Immunomodulatory effects of ursodeoxycholic acid on immune responses | Q68225187 | ||
| A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis | Q68505504 | ||
| Primary biliary cirrhosis | Q68930413 | ||
| High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids | Q69063870 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Trial of penicillamine in advanced primary biliary cirrhosis | Q69887093 | ||
| A prospective trial of D-penicillamine in primary biliary cirrhosis | Q70210395 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 935-938 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Characterisation of patients with a complete biochemical response to ursodeoxycholic acid | |
| P478 | volume | 36 |
| Q73118377 | A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis |
| Q44825279 | A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results |
| Q32028457 | Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis |
| Q35358467 | Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment |
| Q77716502 | Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis |
| Q77872001 | Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q73156200 | Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease |
| Q43605924 | Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis |
| Q77906153 | Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis |
| Q35354776 | Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans |
| Q73574820 | Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis |
| Q36502610 | Fenofibrate for patients with asymptomatic primary biliary cirrhosis |
| Q46640079 | Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"? |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34043010 | Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation |
| Q46959070 | Methotrexate for treatment of primary biliary cirrhosis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q37681567 | Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q56428273 | Primary biliary cirrhosis |
| Q74118375 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q33869324 | Primary biliary cirrhosis: new perspectives in diagnosis and treatment |
| Q73011043 | Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q77386849 | Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses |
Search more.